Kaye Biotech Inc. had the following equity account balances at December 31, 2022: Preferred shares, $2.55, non-cumulative, Authorized: 20,400 shares Issued and outstanding: 5,200 shares Common shares, Authorized: Unlimited Issued and outstanding: 86,000 shares Retained earnings $36,400 On February 1, 2023, 5,200 preferred shares were issued at $7.90 each. The board of directors declared and paid the annual cash dividend on the preferred shares on June 30, 2023, and a 11% common share dividend was declared and distributed on the same day when the market price per common share was $4.30. On October 1, 2023, 20,400 common shares were issued at $4.44 each. Profit earned during 2023 was $410,800. KAYE BIOTECH INC. Statement of Changes in Equity For Year Ended December 31, 2023 291,080 41,400 Required: Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2023. (Amounts to be deducted should be indicated by a minus sign.) Deafarend Batninad Tabal
Kaye Biotech Inc. had the following equity account balances at December 31, 2022: Preferred shares, $2.55, non-cumulative, Authorized: 20,400 shares Issued and outstanding: 5,200 shares Common shares, Authorized: Unlimited Issued and outstanding: 86,000 shares Retained earnings $36,400 On February 1, 2023, 5,200 preferred shares were issued at $7.90 each. The board of directors declared and paid the annual cash dividend on the preferred shares on June 30, 2023, and a 11% common share dividend was declared and distributed on the same day when the market price per common share was $4.30. On October 1, 2023, 20,400 common shares were issued at $4.44 each. Profit earned during 2023 was $410,800. KAYE BIOTECH INC. Statement of Changes in Equity For Year Ended December 31, 2023 291,080 41,400 Required: Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2023. (Amounts to be deducted should be indicated by a minus sign.) Deafarend Batninad Tabal
Chapter1: Financial Statements And Business Decisions
Section: Chapter Questions
Problem 1Q
Related questions
Question

Transcribed Image Text:Kaye Biotech Inc. had the following equity account balances at December 31, 2022:
Preferred shares, $2.55, non-cumulative,
Authorized: 20,400 shares
Issued and outstanding: 5,200 shares
Common shares,
Authorized: Unlimited
Issued and outstanding: 86,000 shares
Retained earnings
$36,400
On February 1, 2023, 5,200 preferred shares were issued at $7.90 each. The board of directors declared and paid the annual cash
dividend on the preferred shares on June 30, 2023, and a 11% common share dividend was declared and distributed on the same day
when the market price per common share was $4.30. On October 1, 2023, 20,400 common shares were issued at $4.44 each. Profit
earned during 2023 was $410,800.
KAYE BIOTECH INC.
Statement of Changes in Equity
For Year Ended December 31, 2023
Comman
291,080
41,400
Required:
Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2023. (Amounts to be
deducted should be indicated by a minus sign.)
Drafarroad
Datained
Total
Subm
Expert Solution

This question has been solved!
Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.
Step by step
Solved in 3 steps

Recommended textbooks for you


Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,

Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,


Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,

Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,

Horngren's Cost Accounting: A Managerial Emphasis…
Accounting
ISBN:
9780134475585
Author:
Srikant M. Datar, Madhav V. Rajan
Publisher:
PEARSON

Intermediate Accounting
Accounting
ISBN:
9781259722660
Author:
J. David Spiceland, Mark W. Nelson, Wayne M Thomas
Publisher:
McGraw-Hill Education

Financial and Managerial Accounting
Accounting
ISBN:
9781259726705
Author:
John J Wild, Ken W. Shaw, Barbara Chiappetta Fundamental Accounting Principles
Publisher:
McGraw-Hill Education